ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most adenocarcinomas.... It is an attractive target for immunotherapy.
- Mechanism
- Curator reviewed
ING-1 is XOMA's proprietary anti-tumor Human Engineered(TM) monoclonal antibody with Triton's Targeted Nano-Therapeutics(TM) (TNT(TM)) System. The TNT(TM) System is an innovative product that ablates tumors by using tiny magnetic spheres delivered systemically with antibodies. The tiny spheres within the tumors are induced to heat by a localized externally applied magnetic field. ING-1, a Human Engineered(TM) monoclonal antibody with high affinity to the Ep-CAM antigen is expressed in high concentrations on many adenocarcinoma tumor cells. The combination of the ING-1 antibody with the TNT(TM) System is intended to create a novel, highly selective, safe, and effective treatment for adenocarcinomas, such as breast, colorectal, lung, ovary and prostate
- Primary indication
- Investigated for use/treatment in cancer/tumors (unspecified).Curator reviewed
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with ING-1, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account